Semaglutide for bone health in type 2 diabetes
Part of Bones, joints & muscles, Hormones & metabolism, Injuries & trauma clinical trials.
This study tests whether the diabetes medication semaglutide (which helps lower blood sugar) can also help protect your bones. It is for people with type 2 diabetes who have low bone density or a history of easy fractures, but not severe osteoporosis.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have type 2 diabetes.
- You are between 50 and 75 years old.
- Your blood sugar control (HbA1c) is between 6.5% and 9%.
- You have low bone density (osteopenia) or have had a broken bone from a minor fall in the last 3 years.
- You have not taken any diabetes medication (except metformin) in the past 8 weeks.
- You have not taken strong bone medications (like bisphosphonates) in the last 2 years, and you do not have severe kidney or liver problems, pancreatitis, or a family history of certain thyroid cancer.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a diabetes medication called a GLP-1 receptor agonist can help improve bone and muscle health in older women with type 2 diabetes who are at risk for osteoporosis. It aims to see if the drug can strengthen bones and prevent falls.
This trial tests whether semaglutide (a diabetes drug) can help protect kidney function in people with type 2 diabetes who already have mild to moderate kidney damage. You will take semaglutide or a placebo and have regular kidney function tests.
This study tests whether the diabetes medication semaglutide can reduce inflammation and improve blood vessel health in people with type 2 diabetes who have no significant heart artery blockages. If you have diabetes and are at moderate to high heart risk but haven't had heart problems, this could help understand the medicine's extra benefits beyond blood sugar control.
This Phase 2 study tests semaglutide (a diabetes and weight-related medicine) to see if it can slow or improve diabetic kidney disease in people with type 1 diabetes. You may be able to join if you have type 1 diabetes for at least 5 years and ongoing signs of kidney damage measured in urine tests.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This trial tests if a new form of semaglutide works as well as the approved drug Ozempic for lowering blood sugar. It's for adults with type 2 diabetes who are already taking metformin and need better sugar control.
Hear when a new Osteoporosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.